Bausch Health Companies (NYSE:BHC) Upgraded at StockNews.com

Bausch Health Companies (NYSE:BHC - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Wednesday.

Several other research analysts also recently commented on BHC. Piper Sandler raised their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a "neutral" rating in a report on Monday, April 29th. Royal Bank of Canada dropped their price objective on Bausch Health Companies from $12.00 to $11.00 and set a "sector perform" rating for the company in a research note on Tuesday, April 23rd. Finally, Jefferies Financial Group decreased their target price on Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, February 20th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $11.33.

Bausch Health Companies Stock Down 0.6 %

Bausch Health Companies stock traded down $0.04 during trading on Wednesday, hitting $7.08. The stock had a trading volume of 2,199,254 shares, compared to its average volume of 2,910,992. The stock's 50 day moving average is $8.91 and its two-hundred day moving average is $8.22. Bausch Health Companies has a 1 year low of $5.86 and a 1 year high of $11.46. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -5.71 and a beta of 0.90.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.14. The business had revenue of $2.41 billion for the quarter, compared to analysts' expectations of $2.29 billion. Bausch Health Companies had a negative return on equity of 2,370.91% and a negative net margin of 5.07%. The firm's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.02 EPS. As a group, equities research analysts anticipate that Bausch Health Companies will post 3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldentree Asset Management LP lifted its position in shares of Bausch Health Companies by 19.6% in the 3rd quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company's stock worth $197,177,000 after purchasing an additional 3,931,234 shares during the period. Nomura Holdings Inc. boosted its position in Bausch Health Companies by 67.7% during the 3rd quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company's stock valued at $148,667,000 after acquiring an additional 7,303,015 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Bausch Health Companies by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company's stock worth $124,285,000 after acquiring an additional 114,862 shares during the period. Hudson Bay Capital Management LP raised its position in shares of Bausch Health Companies by 35.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company's stock worth $94,530,000 after acquiring an additional 3,000,000 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in shares of Bausch Health Companies in the 3rd quarter valued at approximately $57,540,000. Institutional investors own 78.65% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.